newsfilter
← Latest News
Business Wire·

Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US

Company intends to seek a partner for further development of Vicineum Sesen Bio continues to focus on the assessment of potential strategic alternatives Sesen Bio (NASDAQ:SESN) today announced that it has made the strategic decision to voluntarily